Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Chubb
Medtronic
Moodys
Express Scripts
Daiichi Sankyo
Dow
Farmers Insurance
AstraZeneca
US Department of Justice

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,550,433

« Back to Dashboard

Summary for Patent: 7,550,433
Title:Erythropoietin receptor peptide formulations and uses
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Inventor(s): Duliege; Anne-Marie (Palo Alto, CA), Stead; Richard (Bellevue, WA), Leuther; Kerstin (San Jose, CA), Woodburn; Kathryn (Saratoga, CA), Naso; Robert Barnett (Menlo Park, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:11/446,593
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,550,433

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,550,433

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,906,485 Erythropoietin receptor peptide formulations and uses ➤ Subscribe
7,919,461 Erythropoietin receptor peptide formulations and uses ➤ Subscribe
8,324,159 Erythropoietin receptor peptide formulations and uses ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,550,433

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006255081 ➤ Subscribe
Brazil PI0613233 ➤ Subscribe
Canada 2609401 ➤ Subscribe
China 101553242 ➤ Subscribe
Costa Rica 9570 ➤ Subscribe
Eurasian Patent Organization 014528 ➤ Subscribe
Eurasian Patent Organization 200702656 ➤ Subscribe
European Patent Office 1917023 ➤ Subscribe
European Patent Office 2195002 ➤ Subscribe
Israel 187354 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Accenture
Merck
AstraZeneca
Fuji
Novartis
Teva
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot